Figure 3.
Overexpression of CLDN6 is associated with poor outcome in endometrial cancer patients. The overall (A) and 5-year recurrence-free (B) survival for high and low expression of CLDN6 in endometrial cancer subjects are indicated.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.